Pasithea Therapeutics Corp [KTTA] stock prices are up 12.17% to $1.29 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KTTA shares have gain 11.21% over the last week, with a monthly amount glided 11.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
The stock price of Pasithea Therapeutics Corp [KTTA] has been fluctuating between $0.28 and $3.85 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Pasithea Therapeutics Corp [NASDAQ: KTTA] shares were valued at $1.29 at the most recent close of the market. An investor can expect a potential return of 132.56% based on the average KTTA price forecast.
Analyzing the KTTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.0% with Operating Profit Margin at -4808.43%, Pretax Profit Margin comes in at -4696.06%, and Net Profit Margin reading is -4696.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -1.0 and Total Capital is -0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1867 points at the first support level, and at 1.0833 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3467, and for the 2nd resistance point, it is at 1.4033.
Ratios To Look Out For
It’s worth pointing out that Pasithea Therapeutics Corp [NASDAQ:KTTA]’s Current Ratio is 4.02. As well, the Quick Ratio is 4.02, while the Cash Ratio is 2.99.
Transactions by insiders
Recent insider trading involved STEINMAN LAWRENCE, Director, that happened on Nov 28 ’25 when 0.13 million shares were purchased. Chief Executive Officer, Marques Tiago completed a deal on Nov 28 ’25 to buy 33333.0 shares. Meanwhile, Director Dumesnil Simon bought 33333.0 shares on Nov 28 ’25.
